Owing to studies of somatic mutation activation in NSCLC patients, we already know that a series of driver genes, including EGFR, BRAF, KRAS, MET, ALK, and ROS1 were the most frequent mutation genes in LUAD (Hirsch et al., 2017; Shi et al., 2016; Cancer Genome Atlas Research Network 2014). This evidence concerns the gene MET and non-small cell lung carcinoma.